Efficacy and safety of Xin-Li-Fang in the treatment of chronic heart failure:A Randomized, double-blind, placebo-controlled study

INTERVENTION: Xin‐Li‐Fang group:Basal treatment (ACEI or ARB/ß‐blockers/diuretics/with or without digoxin)+Xin‐Li‐Fang Granule;Placebo Group:Basal treatment (ACEI or ARB/ß‐blockers/diuretics/with or without digoxin)+Placebo; CONDITION: Chronic Heart Failure PRIMARY OUTCOME: NT‐proBNP; SECONDARY OUTCOME: NYHA classification;primary end point event;6 minute walking test;Minnesota living with heart failure questionnaire;TCM symptoms evaluation;Colour Sonography; INCLUSION CRITERIA: (1)Age is above 18 years, not restrictions on male or female; (2)Patients who meet the chronic heart failure diagnosis creteria, and have a history of chronic heart failure for more than 3 months, or clinical symptoms of heart failure for more than 3 months; The diagnosis of chronic heart failure was based on the 2018 Guidelines for the Diagnosis and Treatment of Chronic Heart Failure in China; (3)The syndrome differentiation of traditional Chinese medicine is the syndrome of water stopping, Qi deficiency and blood stasis; (4)NYHA classification stage II‐IV; (5)Serum NT‐proBNP>=450pg/ml; (6)Patients have received standard medical treatment for more than 2 wks and no modification of dosage or intravenous administration has been given; (7) To be able to and willing to provide signed informed consent.